Talquetamab‐Related Dysgeusia in Multiple Myeloma Compared to BCMA ‐Targeted Bispecifics and High‐Dose Melphalan
Cancer Medicine · 2025
DOI: 10.1002/cam4.71401 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Cancer Medicine, 2025. Verfasst von Anna Fleischer und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany. Hauptthemen laut MEDLINE: Multiple Myeloma, Antibodies, Bispecific, Dysgeusia, Melphalan. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: IMS and Paula and Rodger Riney Foundation, Dietmar-Hopp-Foundation, Paula and Rodger Riney Foundation and the German Cancer Aid via the MSNZ programme.
Abstract (Originalsprache)
Background
Dysgeusia is a side effect of the anti‐GPRC5DxCD3 bispecific antibody talquetamab (TAL), but other myeloma treatments, such as high‐dose melphalan (MEL) with autologous stem cell transplantation (ASCT), are also known to alter taste perception in patients with multiple myeloma (MM). This study investigates the spectrum, prevalence and severity of dysgeusia in patients receiving TAL and MEL and compares the results with anti‐BCMA bispecifics as a control for T‐cell‐engaging therapies.
Methods
Gustatory and olfactory performance was assessed in 87 MM patients divided into three treatment groups: TAL ( n = 26), MEL/ASCT ( n = 35), and BCMA bispecifics ( n = 26). Evaluations included Taste Strips, Sniffin' Sticks Identification Test 16, and comprehensive questionnaires on taste perception, dietary issues, quality of life (QoL), mood, and treatment compliance.
Results
TAL‐treated patients exhibited severe taste impairment, with 96.2% reporting marked declines. Taste alterations were also observed in patients receiving MEL/ASCT and BCMA bispecifics, though these were less pronounced, affecting 62.9% and 30.8% of cases, respectively. Xerostomia incidence was highest in the TAL group. Patients considering discontinuation of TAL (30%) cited taste alterations as the primary reason. MEL was associated with higher incidences of nausea, vomiting, and appetite loss.
Conclusion
TAL‐associated taste disturbances have a major impact on patients and require further investigation and mitigation strategies. Enhanced patient support, proactive monitoring, and targeted interventions are critical to improving the well‐being and adherence of MM patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany.
- Heidelberg Myeloma Center, Department of Medicine V, University Hospital and Medical Faculty Heidelberg, Heidelberg University, Heidelberg, Germany.
- Institute of Biometry and Epidemiology, University Hospital of Würzburg, Würzburg, Germany.
ORCID-Profile: Anna Fleischer, Leo Rasche
Förderung
- IMS and Paula and Rodger Riney Foundation
- Dietmar-Hopp-Foundation
- Paula and Rodger Riney Foundation and the German Cancer Aid via the MSNZ programme
- Else Kröner-Fresenius Foundation
Zitieren
APA
Fleischer, A., Roll, M., Frenking, J. H., Panther, F., Gelbrich, G., Strunz, P. P., Riedhammer, C., Peter, J., Mersi, J., Waldschmidt, J., Kortüm, M., Einsele, H., Raab, M. S., Maatouk, I., & Rasche, L. (2025). Talquetamab‐Related Dysgeusia in Multiple Myeloma Compared to BCMA ‐Targeted Bispecifics and High‐Dose Melphalan. Cancer Medicine. https://doi.org/10.1002/cam4.71401
Vancouver
Fleischer A, Roll M, Frenking JH, Panther F, Gelbrich G, Strunz PP, et al. Talquetamab‐Related Dysgeusia in Multiple Myeloma Compared to BCMA ‐Targeted Bispecifics and High‐Dose Melphalan. Cancer Medicine. 2025. doi:10.1002/cam4.71401
BibTeX
@article{Fleischer2025,
author = {Fleischer, Anna and Roll, Magdalena and Frenking, Jan H and Panther, Franziska and Gelbrich, Götz and Strunz, Patrick-Pascal and Riedhammer, Christine and Peter, Jessica and Mersi, Julia and Waldschmidt, Johannes and Kortüm, Martin and Einsele, Hermann and Raab, Marc-S and Maatouk, Imad and Rasche, Leo},
title = {Talquetamab‐Related Dysgeusia in Multiple Myeloma Compared to BCMA ‐Targeted Bispecifics and High‐Dose Melphalan},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.71401}
}
EUVIMED